67743-62-8

Upstream product

• 18108-77-5 5-phenylsulfanylpyridin-2(1H)-one 
• 10026-13-8 phosphorus pentachloride 
• 53939-30-3 5-bromo-2-chloropyridine 
• 882-33-7 diphenyldisulfane 
• 13466-38-1 5-bromopyridin-2(1H)-one 
• 3111-52-2 potassium thiophenolate 
• 64064-25-1 2-Amino-5-(phenylthio)pyridin 
• 69045-79-0 2-choro-5-iodopyridine 
• 108-98-5 thiophenol 

Downstream Products

• 877868-60-5 2-chloro-5-(phenylsulfonyl)pyridine 
• 67743-67-3 2-chloro-5-(phenylsulfinyl)pyridine 
• 877866-93-8 C₁₉H₁₃NSO₂F₂ 
• 64064-30-8 (6-phenylsulfanyl-imidazo[1,2-a]pyridin-2-yl)-carbamic acid methyl ester 
• 1233560-94-5 2-hydrazineyl-5-(phenylsulfonyl)pyridine 
• 1450622-13-5 1,1,1,3,3,3-hexafluoro-2-(5'-(phenylsulfonyl)-2,2'-bipyridin-5-yl)-2-propanol 
• 877866-86-9 C₁₉H₁₃NSOF₂ 
• 65367-69-3 5-(benzenesulfonyl)pyridin-2-amine 

Relevant academic research and scientific papers

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart ( e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease.

Cu(ii)-catalyzed sulfide construction: both aryl groups utilization of intermolecular and intramolecular diaryliodonium salt

A sulfur-iodine exchange protocol of diaryliodonium salts with inorganic sulfur salt was developed. Both aryl groups in the diaryliodonium salt were fully exerted in this transformation. Five- to eight-membered sulfur-containing heterocycles were achieved. Note that [1]benzothieno-[3,2-b][1]benzothiophene (BTBT) (an organic field-effect transistor (OFET) material) and Zaltoprofen were efficiently established through this method.

Diaryl thioether compound, and synthetic method and application thereof

The invention discloses a diaryl thioether compound, and a synthetic method and an application thereof. Various diaryl thioether compounds can be obtained through a reaction of a reaction raw material high iodine salt in dimethyl sulfoxide at 60-100DEG C under the action of an odorless sulfuration reagent, an alkali, a metal catalyst and a ligand for 3-12h. Sulfur is introduced in the later stage, so poisoning of sulfur to the metal catalyst and incompatibility of an oxidant in the early stage reaction are avoided; the above inorganic sulfur source is nontoxic and odorless; and two aryl groups in the high iodine salt are fully used, so the atom economy of the method is fully shown. The diaryl thioether compound prepared through the method can be further used to synthesize a photoelectric material BTBT and an anti-inflammatory drug zaltoprofen.

TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

The invention relates to a compound of Formula I or IA and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:

SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS

The present invention relates to novel substituted dihydropyrazolone derivatives, to their preparation and to their therapeutic use as activators of the transcription factor HIF.

Homoleptic zincate-promoted room-temperature halogen-metal exchange of bromopyridines

Homoleptic lithium tri- and tetraalkyl zincates were reacted with a set of bromopyridines. Efficient and chemoselective bromine-metal exchanges were realized at room temperature with a substoichiometric amount of nBu 4ZnLi2·TMEDA reagent (1/3 equiv; TMEDA=N,N,N′,N′-tetramethylethylenediamine). This reactivity contrasted with that of tBu4ZnLi2·TMEDA, which was inefficient below one equivalent. DFT calculations allowed us to rationalize the formation of N...Li stabilized polypyridyl zincates in the reaction. The one-pot difunctionalization of dibromopyridines was also realized using the reagent stoichiometrically. The direct creation of C-Zn bonds in bromopyridines enabled us to perform efficient Negishi-type cross-couplings. Mild zincation! nBu4ZnLi2·TMEDA (in substoichiometric amounts) promoted efficient and chemoselective room-temperature bromine-metal exchange of a range of bromopyridines (see scheme). DFT calculations strongly supported the formation of a stabilized tripyridylzincate, which could be reacted with electrophiles or be directly involved in palladium-catalyzed cross-coupling reactions.

2,5-Disubstituted pyridines: The discovery of a novel series of 5-HT2A ligands

This report describes the effect of replacing the central basic amine present in many known 5-HT2A ligands with an aromatic residue. We targeted the isomeric phenethylpyridines 2 and 3 and these compounds proved to be excellent leads, possessin

Process for the preparation of imidazo [1,2-a] pyridines

Processes are described for the preparation of 2-(methoxycarbonylamino)-6-(phenylsulfinyl) imidazo [1,2-a] pyridine, which is an active anthelmintic agent. The process involves the treatment of a 5-phenylsulfinyl pyridine substituted at the 2-position wit